US imposes 100% tariff on patented drug imports unless co. signs drug pricing deal or agrees to make product in the US, according to White House fact sheet

The US's imposition of a 100% tariff on patented drug imports unless companies comply with pricing deals or shift production to the US marks a significant shift in drug pricing policy.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

IRGC PR says an advanced enemy fighter was hit and crashed in Qeshm, Fars reports

US FX WRAP: Dollar strengthens as Trump stands firm on war with Iran

US imposes 100% tariff on patented drug imports unless co. signs drug pricing deal or agrees to make product in the US, according to White House fact sheet

US imposes 25% tariffs on steel, aluminum, and copper derivatives, White House says

Microsoft (MSFT) hit "audacious" copilot goals after Wall Street input

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Drugmakers face 100% tariff unless they cut prices or produce drugs in the US.
  • Pharmaceutical tariff reduced to 15% on Europe, Japan, South Korea, and Switzerland due to trade deals
  • Tariff can be reduced to 20% if companies move manufacturing to US.
  • Has made 17 pharma deals; signed 13 and negotiating remaining four.
  • Large pharma companies have 120 days to make announcements to avoid 100% tariff
  • Smaller pharmaceutical companies have 180 days to avoid higher tariff
  • Companies that move manufacturing to the US and sign most-favored-nation drug pricing deals with US HHS are exempt from pharmaceutical tariffs
Context

This will likely create immediate pressure on pharmaceutical companies, impacting supply chains and their profitability, while potentially strengthening domestic manufacturing. Additionally, the global reaction could influence market sentiment across equities, currencies, and commodities, particularly for firms heavily reliant on drug imports.

Related headlines

The whole workspace, free to try.

Try it free